Brain Vasodilator Responses in Healthy and Cognitively Impaired Humans

健康和认知障碍人群的脑血管舒张反应

• 批准号: 8397065
• 负责人: JILL NICOLE BARNES
• 金额: $ 1.8万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-14 至 2013-01-13
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8397065
• 关键词: Address; Adult; Age; Aging; Alzheimer' s Disease; Attenuated; Blood Vessels; Blood flow; Brain; Carbon Dioxide; Cardiovascular Diseases; Cardiovascular system; Carotid Artery Injuries; Cell Count; Cerebrovascular Circulation; Cerebrum; Cognition; Cognitive; Cognitive aging; Complement; Defect; Dementia; Diabetes Mellitus; Disease; Early identification; Elderly; Epidemiologic Studies; Forearm; Functional disorder; Goals; Heart; Human; Hypertension; Impaired cognition; Indomethacin; Measures; Mediating; Methods; Pathology; Pathway interactions; Patients; Peripheral; Phenotype; Physiological; Physiology; Prevention; Prostaglandins; Protocols documentation; Regulation; Risk; Risk Factors; Role; Staging; Stem cells; Testing; Therapeutic Intervention; Training; Transplantation; Vasodilation; Vasodilator Agents; aging population; base; cerebrovascular; cognitive function; insight; meetings; middle cerebral artery; mild neurocognitive impairment; mouse model; normal aging; novel; reactive hyperemia; regenerative; response; translational study

DESCRIPTION (provided by applicant): The overall goal of this application is to study cerebral microvascular vasodilator function in young and old humans and test hypotheses broadly related to microvascular function and cognition. This project will serve as a vehicle to build upon the applicant's training in cardiovascular aging and integrate with the cerebrovascular changes associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease. Recent evidence suggests that microvascular dysfunction is a major contributing factor to MCI, the transitional stage between normal aging and dementia or Alzheimer's disease. Because Alzheimer's patients demonstrate systemic endothelial dysfunction and reduced endothelial progenitor cells (EPCs), it is likely that MCI patients have a similar phenotype. To address our overall goal we will systematically evaluate microvascular vasodilator function in humans with and without MCI. In Aim 1 we will determine if cerebral and peripheral vasodilator responses are blunted in MCI patients by comparing CO2-mediated vasodilation in the middle cerebral artery (MCA) and the forearm blood flow response to reactive hyperemia in 3 groups: 1) young healthy adults; 2) cognitively intact older adults; and 3) older adults with MCI. In Aim 2 we will determine if a loss of vasodilating prostaglandins explains the reduction in MCA vasodilator responses to CO2 by comparing the effects of indomethacin on CO2-mediated vasodilation in the MCA in the same 3 groups. We expect a loss of prostaglandin-mediated vasodilator mechanisms in both the intact older subjects and MCI patients. In Aim 3 we will determine if blunted EPC regenerative capacity accompanies the reduction in cerebral vasodilator responses to CO2. We will determine the regenerative capacity by assessing reendothelialization using a carotid artery injury mouse model after transplantation of human EPCs from 3 groups: 1) young healthy adults; 2) older cognitively intact adults; 3) older adults with MCI. We expect that EPC regenerative capacity is greatest in young subjects, intermediate in older adults and reduced in MCI patients and correlated with CO2-mediated cerebral vasodilation. In summary, we have a comprehensive plan to investigate cerebral vasodilator function in humans and how it is altered by age or cognitive status. The use of a stepped hypercapnic ventilatory protocol will permit us to assess graded vasodilator responses in the MCA in a way that is non-invasive yet conceptually similar to the tests of vascular function in the forearm and heart that have provided great mechanistic understanding of microvascular pathology in cardiovascular disease. The studies with indomethacin will permit us to test the role of vasodilating prostaglandins in the loss of vasodilator function with aging and MCI. The examination of EPC regenerative capacity further explores the notion that microvascular dysfunction is an underlying factor in MCI. Together this approach will provide significant insight into the role of microvascular dysfunction in cognitive impairment and permit the candidate to develop translational expertise in the mechanisms of cerebral blood flow regulation.

描述（由申请人提供）：本申请的总体目标是研究年轻人和老年人的脑微血管舒张功能，并测试与微血管功能和认知广泛相关的假设。该项目将作为一种工具，以建立在申请人的心血管老化的培训和整合与轻度认知障碍（MCI）和阿尔茨海默病相关的脑血管变化。最近的证据表明，微血管功能障碍是MCI的主要促成因素，MCI是正常衰老和痴呆或阿尔茨海默病之间的过渡阶段。由于阿尔茨海默氏症患者表现出全身性内皮功能障碍和内皮祖细胞（EPCs）减少，MCI患者可能具有相似的表型。为了实现我们的总体目标，我们将系统地评估微血管扩张功能在人类与MCI。在目标1中，我们将通过比较3组大脑中动脉（MCA）中CO2介导的血管舒张和前臂血流对反应性充血的反应来确定MCI患者的脑和外周血管舒张反应是否减弱：1）年轻健康成人; 2）认知功能完好的老年人; 3）MCI老年人。在目标2中，我们将通过比较吲哚美辛对相同3组中MCA中CO2介导的血管舒张的影响，确定血管舒张素的丧失是否解释了MCA血管舒张剂对CO2反应的降低。我们预计，在完整的老年受试者和MCI患者中，胰高血糖素介导的血管扩张机制均丧失。在目标3中，我们将确定是否钝化EPC再生能力伴随着脑血管舒张反应CO2的减少。我们将通过使用颈动脉损伤小鼠模型在移植来自3组的人EPC后评估再内皮化来确定再生能力：1）年轻健康成人; 2）认知完整的老年人; 3）患有MCI的老年人。我们预计EPC再生能力在年轻受试者中最大，在老年人中居中，在MCI患者中降低，并与CO2介导的脑血管舒张相关。总之，我们有一个全面的计划来研究人类的脑血管舒张功能，以及它是如何被年龄或认知状态改变的。使用阶梯式高碳酸血症缓解方案将使我们能够以一种非侵入性但在概念上类似于前臂和心脏中血管功能测试的方式评估MCA中的分级血管扩张剂反应，这些测试提供了对心血管疾病中微血管病理学的深入机械理解。对消炎痛的研究将使我们能够测试血管扩张前列腺素在随着衰老和轻度认知障碍而丧失血管扩张功能中的作用。EPC再生能力的检查进一步探讨了微血管功能障碍是MCI的潜在因素的概念。总之，这种方法将提供显着的洞察微血管功能障碍在认知障碍中的作用，并允许候选人开发脑血流调节机制的翻译专业知识。